The current medications vary in mechanism and magnitude: Semaglutide (Ozempic) targets GLP-1 receptors - around 15% average weight loss Tirzepatide (Mounjaro) targets GLP-1 + GIP - around 20% weight loss, often better GI tolerance Retatrutide (Phase 3 Trials) targets three receptors around 24% weight loss in trials, with broader metabolic effects The real risk is muscle mass loss
More serious concerns include a possible increased risk of pancreatitis (inflammation of the pancreas) and, in animal studies, thyroid C-cell tumors
For a prospectus or summary prospectus with this and other information about Roundhill ETFs please call 1-855-561-5728 or visit the website at www.roundhillinvestments.com/etf/OZEM
Canadian Market Considerations Future Developments Frequently Asked Questions Glossary References Understanding Mazdutide and Retatrutide: The Next Generation of Weight Loss Peptides The obesity treatment landscape has transformed dramatically over the past five years
Fermentable fibers are unique because they arent just roughage, but serve as fuel and nourishment for your gut microbiome (the beneficial bacteria in your gut)
We understand the temptation especially with medication shortages and high out-of-pocket costs